Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 140Observational 6Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1

Interventions

3-Iodobenzylguanidine 2Gemcitabine 2Powders 2Suspensions 2balstilimab 2leronlimab 2ruxolitinib 2talquetamab 2Abiraterone Acetate 1Alpelisib 1Androgen Antagonists 1Asparaginase 1Bone Marrow Transplantation 1Capecitabine 1Cyclophosphamide 1Docetaxel 1Eflornithine 1FANG vaccine 1HMPL-013 1Hydrocortisone 1Immunotherapy, Adoptive 1Insulin Infusion Systems 1LY3023414 1Magnetic Resonance Spectroscopy 1Methionine 1Nivolumab 1Paclitaxel 1Peripheral Blood Stem Cell Transplantation 1Prednisolone 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × cemiplimab × 1 year × Clear all
NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals

Approved for marketing
DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡